 | |
| Clinical data | |
|---|---|
| Trade names | Epidaza, Hiyasta |
| Other names | Chidamide, HBI-8000 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H19FN4O2 |
| Molar mass | 390.418 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tucidinostat (INN, also known aschidamide and sold under the brand namesEpidaza andHiyasta) is ahistone deacetylase inhibitor (HDI) developed in China.[1] It was also known asHBI-8000.[2] It is abenzamide HDI and inhibits Class IHDAC1,HDAC2,HDAC3, as well as Class IIbHDAC10.[3]
Tucidinostat is approved by the Chinese FDA for relapsed or refractoryperipheral T-cell lymphoma (PTCL) and hasorphan drug status in Japan.[2][better source needed] In Japan, it was approved for relapsed or refractoryadult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.[4]
Tucidinostat is being researched as a treatment forpancreatic cancer.[5][6][7] However, it is notUS FDA approved for the treatment of pancreatic cancer.
